Date: January 19, 2023
Time: 5:30 - 8:00 pm ET
Location: Hotel Colonnade, 180 Aragon Ave, Coral Gables, FL 33134 - Colonnade Ballroom
Fee: Complimentary
SNMMI has applied for 1.5 hours of CE Credit for this in-person event.
Please note that seating is limited and registration will be available on a first-come, first-served basis.
SCHEDULE
5:30 pm
Registration/Networking Reception
6:00 pm
Dinner is Served
6:30-8:00 pm
Educational Program
Several new radiopharmaceuticals are now being used in both large academic and small practice settings to stage and identify local and metastatic prostate cancer, including the recently approved Ga-68 PSMA-11 and 18F-DCFPyL. In addition, the FDA in March approved Lu 177 vipivotide tetraxetan to treat PSMA-positive metastatic castration-resistant prostate cancer. Given these new advancements in diagnosis and treatment, the panel will present a comprehensive, interactive session addressing the changing landscape of prostate cancer patient management.
6:30 - 6:35 pm
Welcome and Introductions
Frankis Almaguel, MD, PhD
6:35 - 6:55 pm
The Role of Theranostics
Frankis Almaguel, MD, PhD, Director, Molecular Imaging and Therapeutics Program, Loma Linda University Cancer Center
6:55 - 7:15 pm
The Pathology of Prostate Cancer
David Molina Rios MD, Pathologist, Bayfront Health, Miami, FL
7:15 - 7:35 pm
Urologist's Perspective
Rafael Antun, MD, University of Miami Hospital and Clinics, Miami, FL
7:35 - 7:45 pm
Patient's Perspective
Richard Humphreys
7:45 - 8:00 pm
Q&A and Panel Discussion
Please note: SNMMI is committed to ensuring that appropriate and necessary health and safety protocols will be in place for this event. We will follow all Centers for Disease Control and Prevention (CDC) safety protocols and recommendations and will comply with all federal, state, and local regulations in force at the time of the event.
CE Credit applications for physicians, pharmacists, and technologists are pending. Check back for updates regarding CE Credit status.
This event is supported through a medical education grant from Novartis.